Stay updated on Oral Azacitidine with Pembrolizumab in Metastatic Melanoma Clinical Trial
Sign up to get notified when there's something new on the Oral Azacitidine with Pembrolizumab in Metastatic Melanoma Clinical Trial page.

Latest updates to the Oral Azacitidine with Pembrolizumab in Metastatic Melanoma Clinical Trial page
- Check5 days agoChange DetectedThe page now shows Revision: v3.0.2 (replacing v3.0.1), and the Back to Top element has been removed.SummaryDifference0.1%
- Check12 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.1%
- Check19 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and location, as well as the introduction of various chemical compounds related to skin and connective tissue diseases. Notably, both azacitidine and pembrolizumab have been removed from the page.SummaryDifference2%
- Check26 days agoNo Change Detected
- Check34 days agoChange DetectedThe page has updated its version from v2.16.11 to v2.16.12 and has removed several past dates from February 2025 while adding new dates in August 2025.SummaryDifference0.5%
- Check41 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check48 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.8%
Stay in the know with updates to Oral Azacitidine with Pembrolizumab in Metastatic Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Oral Azacitidine with Pembrolizumab in Metastatic Melanoma Clinical Trial page.